Pfizer Inc. (NYSE:PFE) Shares Sold by IQ EQ FUND MANAGEMENT IRELAND Ltd

Key Points

• IQ EQ Fund Management Ireland Ltd significantly reduced its stake in Pfizer Inc. by 57.9%, ending the first quarter with 108,688 shares valued at approximately $2.75 million.
• Several hedge funds have adjusted their positions in Pfizer, with a notable increase of 97.2% in holdings from Gould Capital LLC during the fourth quarter.
• Analysts have mixed views on Pfizer's stock, with the average target price set at $28.28 and ratings ranging from "sell" to "strong buy," indicating varied investor sentiment.

IQ EQ FUND MANAGEMENT IRELAND Ltd cut its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 57.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 108,688 shares of the biopharmaceutical company's stock after selling 149,622 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd's holdings in Pfizer were worth $2,754,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in PFE. William B. Walkup & Associates Inc. increased its position in shares of Pfizer by 1.2% during the 4th quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock worth $1,044,000 after purchasing an additional 454 shares during the last quarter. Members Trust Co raised its stake in shares of Pfizer by 2.1% in the 1st quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock valued at $587,000 after acquiring an additional 467 shares during the period. Sutton Place Investors LLC raised its position in Pfizer by 5.6% in the first quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock valued at $224,000 after purchasing an additional 472 shares during the period. Bellevue Group AG grew its stake in shares of Pfizer by 0.3% in the fourth quarter. Bellevue Group AG now owns 141,560 shares of the biopharmaceutical company's stock valued at $3,756,000 after buying an additional 485 shares in the last quarter. Finally, Gould Capital LLC boosted its holdings in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 493 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have issued reports on PFE. The Goldman Sachs Group boosted their price target on shares of Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. UBS Group raised their price target on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Cantor Fitzgerald started coverage on Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price for the company. BMO Capital Markets lowered their price objective on Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. Finally, HSBC dropped their price objective on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $28.28.

Pfizer Stock Up 0.9%

PFE stock opened at $23.49 on Monday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.32. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The company has a market cap of $133.55 billion, a price-to-earnings ratio of 17.02, a price-to-earnings-growth ratio of 0.85 and a beta of 0.52. The company has a fifty day moving average price of $24.36 and a 200 day moving average price of $24.55.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.3%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.